Anavex Life Sciences Stock News

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET

AVXL reported positive topline data from their trial for Rett syndrome in adults on Feb 1, 2022. However, the results were met with much skepticism or cynicism, due to changes to the trial's endpoints

Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Wednesday, February 9, 2022, 4:30 pm ET

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Announces Positive Phase 1 Data For Anktiva In HIV ImmunityBio, Inc. (NASDAQ: IBRX) announ

The stock price of Anavex Life Sciences Corp (NASDAQ: AVXL) fell by over 13% during intraday trading today. This is why it happened.

Announcing topline data from its AVATAR trial for ANAVEX2-73 (blarcamesine), Anavex Life Sciences (AVXL) said that the Phase 3 study met primary and secondary efficacy endpoints in

Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome Company to host a webcast today at 8:30 a.m. ET NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) disorders, today reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX ® 2-73 ( blarcamesine ) in adult female patients with Rett syndrome and demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint as well as for all the secondary efficacy endpoints.

Anavex Life Sciences Corp AVXL reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. [LIVE NOW ON YOUTUBE] Click Here to Watch�

Gainers: Integral Ad Science (IAS) +14%, Anavex Life Sciences (AVXL) +8%, Algoma Steel (ASTL) +5%, EMCORE (EMKR) +4%, CymaBay Therapeutics (CBAY) +4%.Losers: Apyx Medical (APYX)

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Anavex's long story is coming to a climax this year. The company will announce topline data from the Alzheimer's trial by 2H 2022.